ENTITY

Amicus Therapeutics (FOLD US)

5
Analysis
Health CareUnited States
Amicus Therapeutics, Inc. is a biopharmaceutical company that develops orally-administered, small molecule drugs to treat human genetic diseases. The drugs, called pharmacological chaperones, are being developed to treat Fabray, Gaucher, and Pompe disease.
more
26 Feb 2022 08:00Issuer-paid

SPAC Talk: Why Underwriters Really Matter in SPAC Land

KEY HIGHLIGHTS Drip, drip, drip: Only two new SPAC IPOs were completed in the past week—media & entertainment SPAC PowerUP Acquisition Corp...

Logo
987 Views
Share
22 Dec 2021 23:00

Continued Absence Of Breakdowns Is A Positive Sign; Many Bottoms-Up Stock Recommendations

As long as the Russell 2000 index (IWM) is above $208, the Russell Micro Caps index (IWC) is above $134-$135, and the S&P 500 is above 4495, we...

Logo
334 Views
Share
bearishS&P 500 INDEX
22 Apr 2020 08:38

U.S. Equity Strategy: Several Indicators Suggest a Pullback Likely

Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight...

Logo
448 Views
Share
bearishWuxi Biologics
14 Jan 2019 04:16

WuXi Biologics – The Foxconn or Qualcomm of Global CDMO?

During the first week of 2019, we visited Wuxi Biologics (Cayman) Inc (2269 HK) headquarters in Shanghai, as well as spend time touring the lab....

Logo
860 Views
Share
03 Dec 2016 14:42

Amicus Therapeutics: New Long Position. Another Contrarian Play with Upcoming Catalysts

We analyzed Amicus Therapeutics Inc (FOLD US) product pipeline after the stock's recent fall. Investors have been over-pessimistic on the stock...

No more insights
x